NeurologyNovartis pays $125M for Sironax brain delivery platformNovartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an option it secured from the U.S.-Chinese biotech in July 2025. Sironax will … more ➔
MacrocycleOrbis lands $1.4B macrocycle partnership with NovoNovo has entered a collaboration and licensing agreement with Danish biotech Orbis Medicines worth up to $1.4 billion (€1.2 billion) to discover oral macrocycle drugs for cardiometabolic diseases. … more ➔
licensingRoche taps Dualitas in $1B bispecific dealRoche will pay Dualitas Therapeutics $36.5 million upfront in a research collaboration that could be worth up to $1 billion to discover bispecific antibodies for immune and inflammatory diseases. more ➔
fundraisingSensorion files confidentially for potential U.S. IPOThe French hearing-loss biotech has taken the first formal step toward a potential U.S. listing, as it advances its remaining gene therapy program into the clinic. more ➔
EntrepreneurshipThe Strüngmann legacy, passed onThomas and Andreas Strüngmann have spent decades building pharmaceutical companies and backing biotech entrepreneurs, most famously BioNTech. Now, as a new generation takes a larger role in their family … more ➔
heart attackResoTher heart data clear acquisition hurdle, set up 200-patient trialDanish biotech ResoTher Pharma’s heart attack drug RTP-026 was well tolerated and showed early efficacy signals in a 66-patient Phase 2a trial, according to results announced Sept. 14 that clear a key … more ➔
myelomaGSK returns to Chimagen for up to $750M myeloma trispecificGSK has agreed to acquire full global rights to a preclinical trispecific T-cell engager for multiple myeloma from China-based Chimagen Biosciences in a deal worth up to $750 million (€650 million), … more ➔
clinical dataAgomab’s IPF drug clears first patient testAgomab Therapeutics’ inhaled idiopathic pulmonary fibrosis (IPF) drug AGMB-447 showed lung-restricted exposure and inhibited its intended target in its first patient trial. The company plans to move … more ➔
MaaT PharmaMaaT’s bid to overturn microbiome approval refusal suffers setbackMaaT Pharma has received a “negative trend” opinion in response to its request for EMA to re-examine its opposition to approving a microbiome therapy. more ➔
clinical dataAxoltis ALS drug misses Phase 2 endpointFrench biotech Axoltis Pharma’s NX210c missed the primary endpoint of a Phase 2 trial in amyotrophic lateral sclerosis (ALS), but post-hoc analyses showing slower functional decline are giving the … more ➔
